Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Group 1 - The article discusses Compugen (CGEN) and its potential best-in-class anti-PVRIG COM701, which is shifting to target PSOC patients [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Compugen or the broader biotech industry [4] - There are no disclosures regarding stock positions or plans to initiate positions in the companies mentioned within the next 72 hours [3]